Searched for
LAL PATHLABS SHARES
LIC dividend alert! Last day to buy insurance behemoth’s shares for Rs 10 dividendLIC has fixed June 25 as the record date for its Rs 10 final dividend, making today the last opportunity for investors to buy shares to qua...- Dividends & bonus issues: LIC, Asian Paints among 35 stocks turning ex-record date this week. How many do you own?Around 35 companies, including LIC, HUL, Asian Paints and IndusInd Bank, have fixed record dates for dividends, bonus issues and buybacks i...
- JioBlackRock Flexi Cap Fund exits Adani Enterprises, Adani Ports and 3 other companies; adds Tata Motors and 14 more stocksJioBlackRock Flexi Cap Fund exited Adani Enterprises, Adani Ports and three other stocks in May while adding Tata Motors and 14 new stocks ...
- Ahead of Market: 10 things that will decide stock market action on WednesdayIndian equities extended gains for a third straight session, with Sensex and Nifty rising on optimism over the Iran-US peace framework and ...
- Sunil Singhania-backed Abakkus Small Cap Fund adds 3 new stocks, increases stake in HDFC Bank, SBI and 49 othersSunil Singhania's Abakkus Small Cap Fund added three new stocks in May, including Tanla Platforms and Intellect Design Arena. The fund also...
- Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...
- Add Dr Lal Pathlabs, target price Rs 2,910: HDFC SecuritiesHDFC Securities has an 'add' call on Dr Lal Pathlabs with a target price of Rs 2910. The company reported a total income of Rs 621.80 crore...
- JM Financial upgrades Dr Lal Pathlabs to Buy, target price Rs 3,600JM Financial recommends buying Dr. Lal Pathlabs with a target price of Rs 3,600, citing a potential 25% upside. The company's Q3 earnings s...
- Dr Lal PathLabs Q2 Results: Net profit rises 53%YoY to Rs 111 croreDr Lal PathLabs reported a Rs 72 crore net profit during the corresponding period of the previous year. Revenues rose 12.6% to Rs 601 crore...
- Dr Lal Pathlabs skids 3% as Q3 net profit drops 39% YoYThe company’s EBITDA (earnings before interest, tax, depreciation and amortization) dipped 21.3 per cent to Rs 109 crore in Q3 FY22 over Rs...
- Market Movers: What spurred rally in NCC, Dr Lal PathlabsDespite a weakness in the headline indices, as many as 40 stocks on the National Stock Exchange gave buy signal based on MACD indicators.
- Dr Lal PathLabs Q2 results: Net profit up 7.5% to Rs 87 crRevenue from operations stood at Rs 431.9 crore for the quarter under consideration. It was Rs 365.6 crore for the same period a year ago, ...
- Trending stocks: Dr. Lal Pathlabs shares down over 2%A total of 1,483 shares changed hands on the counter till 10:48AM (IST).
- Buy Dr Lal PathLabs, target price Rs 1,860: CLSAThe brokerage has lowered volume assumptions by 2-5 per cent over FY20-FY22.
- Dr Lal PathLabs Q3 net profit up 19% to Rs 54.9 croreIts revenue from operations rose to Rs 327.9 crore during the quarter under review.
- 3 stocks are in the pink of health in a choppy market, drawing eyeballsThyrocare has shed 7.27 per cent for the year to date.
- Dr Lal PathLabs to acquire 70 pc stake in Amins Pathology Referral LaboratoryThe acquisition will further strengthen the company's network in Gujarat and adjoining areas
- Buy Dr. Lal Pathlabs, target Rs 1,249: Dharmesh ShahBuy Dr. Lal Pathlabs Ltd. at a price target of Rs 1249.0 and a stoploss at Rs 1136 from entry point.
- Buy Dr Lal Pathlabs, target Rs 1,235: Dharmesh ShahBuy Dr. Lal Pathlabs Ltd. at a price target of Rs 1235.0 and a stoploss at Rs 1148 from entry point.
- Nomura upgrades Dr Lal PathLabs to 'buy' from 'neutral'The brokerage said growth in recent times in Dr Lal PathLabs has been hit by demonetisation but it remains constructive on long term growth...
Load More
